US equities
|
NVDA
$181.60
▼-9.26%
MU
$656.39
▼-17.46%
AMD
$404.40
▼-17.26%
TSLA
$343.69
▼-10.77%
AAPL
$344.17
▼-1.53%
SNDK
$806.43
▼-22.26%
MSFT
$535.93
▼-3.58%
AMZN
$260.21
▼-2.19%
NVDA
$181.60
▼-9.26%
MU
$656.39
▼-17.46%
AMD
$404.40
▼-17.26%
TSLA
$343.69
▼-10.77%
AAPL
$344.17
▼-1.53%
SNDK
$806.43
▼-22.26%
MSFT
$535.93
▼-3.58%
AMZN
$260.21
▼-2.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Aquestive Therapeutics, Inc. - Common Stock
(NQ:
AQST
)
3.660
-0.140 (-3.68%)
Delayed Quote
Updated: 4:00 PM EST, Nov 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
Today 7:00 EST
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive (AQST) Q3 2026 Earnings Call Transcript
↗
November 04, 2026
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding.
Via
The Motley Fool
Topics
Earnings
Supply Chain
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
↗
November 04, 2026
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is...
Via
MarketBeat
Topics
Earnings
Aquestive Therapeutics (NASDAQ:AQST) Q3 2026 Revenue Miss Weighs on Shares Despite Anaphylm Progress
↗
November 03, 2026
Via
Chartmill
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 03, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
October 27, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
October 15, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
October 14, 2026
From
Eton Pharmaceuticals; Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
September 17, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
September 01, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive (AQST) Q2 2026 Earnings Call Transcript
↗
August 18, 2026
Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.
Via
The Motley Fool
Topics
Earnings
Aquestive Therapeutics Q2 Earnings Call Highlights
↗
August 12, 2026
Aquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis,...
Via
MarketBeat
Topics
Earnings
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 11, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 10, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
July 29, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
July 07, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST Q1 2026 Earnings Call Transcript
↗
May 14, 2026
AQST Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Aquestive Therapeutics Q1 Earnings Call Highlights
↗
May 14, 2026
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of...
Via
MarketBeat
Topics
Earnings
Wondering what's happening in today's after-hours session?
↗
May 13, 2026
Via
Chartmill
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
May 12, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
May 06, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
May 04, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
May 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AQUESTIVE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
May 01, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role
April 29, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AQUESTIVE DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST
April 28, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors They Have Until May 4th to Seek Lead Plaintiff Role
April 21, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
